146 related articles for article (PubMed ID: 29085664)
1. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.
Wegert J; Vokuhl C; Ziegler B; Ernestus K; Leuschner I; Furtwängler R; Graf N; Gessler M
J Pathol Clin Res; 2017 Oct; 3(4):234-248. PubMed ID: 29085664
[TBL] [Abstract][Full Text] [Related]
2. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
4. Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.
Rastegar B; Andersson N; Petersson A; Karlsson J; Chattopadhyay S; Valind A; Jansson C; Durand G; Romerius P; Jirström K; Holmquist Mengelbier L; Gisselsson D
Clin Cancer Res; 2023 Jul; 29(14):2668-2677. PubMed ID: 37140929
[TBL] [Abstract][Full Text] [Related]
5. Bilateral wilms tumor with TP53-related anaplasia.
Popov SD; Vujanic GM; Sebire NJ; Chagtai T; Williams R; Vaidya S; Pritchard-Jones K
Pediatr Dev Pathol; 2013; 16(3):217-23. PubMed ID: 23387809
[TBL] [Abstract][Full Text] [Related]
6. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
7. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
[TBL] [Abstract][Full Text] [Related]
8. [Anaplastic type of Wilms' tumour].
Vujanić GM; Aleksandrović S
Srp Arh Celok Lek; 1990; 118(9-10):353-6. PubMed ID: 1966350
[TBL] [Abstract][Full Text] [Related]
9. Anaplasia in Wilms tumor: A critical review.
Vujanić GM; Mifsud W
Pediatr Blood Cancer; 2024 Apr; ():e31000. PubMed ID: 38605554
[TBL] [Abstract][Full Text] [Related]
10. Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors.
Treger TD; Chagtai T; Butcher R; Cresswell GD; Al-Saadi R; Brok J; Williams RD; Roberts C; Luscombe NM; Pritchard Jones K; Mifsud W
Transl Oncol; 2018 Dec; 11(6):1301-1306. PubMed ID: 30172241
[TBL] [Abstract][Full Text] [Related]
11. Association of TP53 polymorphisms on the risk of Wilms tumor.
Andrade RC; Cardoso LC; Ferman SE; Faria PS; Seuánez HN; Achatz MI; Vargas FR
Pediatr Blood Cancer; 2014 Mar; 61(3):436-41. PubMed ID: 24038938
[TBL] [Abstract][Full Text] [Related]
12. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
13. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of F(18)-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilms' tumour: correlation with conventional imaging, pathology and immunohistochemistry.
Begent J; Sebire NJ; Levitt G; Brock P; Jones KP; Ell P; Gordon I; Anderson J
Eur J Cancer; 2011 Feb; 47(3):389-96. PubMed ID: 21074411
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic Wilms' tumor: clinical and pathologic studies.
Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
[TBL] [Abstract][Full Text] [Related]
16. Results of Wilms' tumour management in two tertiary-care hospitals in Asia.
Sen S; Kadamba P; Al-AbdulAaly M; Mammen KE; Ahmed S
Pediatr Surg Int; 1998 Jan; 13(1):42-4. PubMed ID: 9391203
[TBL] [Abstract][Full Text] [Related]
17. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of P53 protein in nephroblastoma: a predictor of unfavorable prognosis.
Morgan ED; Yahaya JJ; Ngaiza AI; Othieno E; Livex OA
J Egypt Natl Canc Inst; 2023 Jul; 35(1):23. PubMed ID: 37518096
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biologic significance of nuclear unrest in Wilms tumor.
Hill DA; Shear TD; Liu T; Billups CA; Singh PK; Dome JS
Cancer; 2003 May; 97(9):2318-26. PubMed ID: 12712489
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]